Front Cover -- Pulmonary Adenocarcinoma: Approaches to Treatment -- Pulmonary Adenocarcinoma: Approaches to Treatment -- Copyright -- List of Contributors -- Preface -- Contents -- 1 - The Surgical Management of Pulmonary Adenocarcinoma -- INTRODUCTION -- STAGING -- Initial Staging: Imaging -- Pathologic Staging: Tissue Diagnosis for Suspected Lung Cancer -- Endobronchial and Transbronchial Biopsy -- Surgical Lung Biopsy -- Pathologic Mediastinal Assessment -- ASSESSING SURGICAL CANDIDACY -- Smoking Cessation -- Assessment of Cardiovascular Risk -- Assessment of Pulmonary Function -- SURGICAL MANAGEMENT OF LUNG CANCER -- Early-Stage Lung Cancer -- Locally Advanced Lung Cancer -- T3N1 Tumors -- N2 Disease -- T4 Tumors -- Superior Sulcus Tumors -- Oligometastatic Disease -- SURGICAL APPROACH TO LUNG CANCER -- Open Lobectomy -- Video-Assisted Thoracoscopic Surgery Lobectomy -- Robotic Lobectomy -- Uniportal and Subxiphoid Lobectomy -- IMPORTANT SURGICAL CONSIDERATIONS -- Extent of Resection -- Extent of Lymph Node Resection -- CONCLUSION -- REFERENCES -- FURTHER READING -- 2 - Pulmonary Adenocarcinoma-Pathology and Molecular Testing -- INTRODUCTION -- HISTOLOGICAL CLASSIFICATION -- CLINICAL RELEVANCE OF ADENOCARCINOMA SUBTYPE CLASSIFICATION -- Lepidic Predominant Adenocarcinoma (Good Prognosis) -- Acinar/Papillary Predominant Adenocarcinoma (Intermediate Prognosis) -- Micropapillary and Solid Predominant Adenocarcinoma (Poor Prognosis) -- Invasive Mucinous Adenocarcinoma -- PATHOLOGICAL STAGING OF LUNG ADENOCARCINOMA-UICC/AJCC EIGHTH EDITION -- MOLECULAR CLASSIFICATION -- TRANSCRIPTOMIC CLASSIFICATIONS -- Terminal Respiratory Unit Subtype -- Proximal Inflammatory Subtype -- Proximal Proliferative Subtype -- ONCOGENIC DRIVER MUTATIONS AND MOLECULAR TESTING IN LUNG ADENOCARCINOMA -- Molecular Testing Methods -- EPIDERMAL GROWTH FACTOR RECEPTOR.

Secondary Resistance Mutations -- Activation of Bypass Pathways -- Activation of Downstream Pathways -- Histologic Transformation -- Epidermal Growth Factor Receptor Mutation Testing -- Nontargeted assays -- Targeted assays -- ANAPLASTIC LYMPHOMA KINASE -- ROS1 -- ALK AND ROS1 TESTING -- Break Apart FISH Assay -- Reverse Transcription-Polymerase Chain Reaction -- Fusion Protein Detection of ALK and ROS1 by IHC -- Next-Generation Sequencing -- OTHERS DRIVER ONCOGENES -- MET -- KRAS -- BRAF -- RET -- NTRK1 -- HER2 -- LIQUID BIOPSIES -- Circulating Tumor Cells -- Circulating Tumor DNA -- Targeting Specific Molecular Alterations -- Targeting Multiple Molecular Alterations -- Clinical Applications -- Assessing Tumor Burden -- Characterizing Resistance Mechanisms -- Monitoring Response to Therapy -- PROGRAM DEATH LIGAND 1 -- Program Death Ligand 1 Testing -- CONCLUSIONS -- REFERENCES -- 3 - Adjuvant and Neoadjuvant Therapy in Non-Small-Cell Lung Cancer -- INTRODUCTION -- ADJUVANT CHEMOTHERAPY -- STAGE I DISEASE -- CHOICE OF CHEMOTHERAPY -- ADJUVANT RADIATION THERAPY -- NEOADJUVANT CHEMOTHERAPY -- MOLECULARLY TARGETED THERAPY -- IMMUNOTHERAPY -- NEOADJUVANT IMMUNOTHERAPY -- CONCLUSIONS AND FUTURE DIRECTIONS -- REFERENCES -- 4 - Management of Locally Advanced Lung Cancer -- INTRODUCTION -- ANATOMY -- SCREENING -- MANIFESTATIONS -- Symptoms -- Paraneoplastic Syndromes -- WORKUP -- Imaging -- Sputum Cytology -- Mediastinoscopy -- Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration -- Fiberoptic Bronchoscopy with Bronchoalveolar Lavage -- HISTOLOGY -- Adenocarcinoma -- Squamous Cell Carcinoma -- Large-Cell Lung Carcinoma -- Molecular Analysis -- STAGING (EIGHTH EDITION) (TABLES 4.3 AND 4.4) -- Pleural Invasion -- MANAGEMENT -- Smoking Cessation -- RESECTABLE LA-NSCLC -- Induction Chemotherapy -- Trimodality -- SUPERIOR SULCUS TUMORS.

Postoperative Radiation Therapy -- Radiation Alone -- Postoperative Chemoradiation -- Adjuvant Chemotherapy -- UNRESECTABLE LA-NSCLC -- Radiation Alone -- Sequential Chemoradiation -- Sequential and Concurrent Chemoradiotherapy -- Consolidation Chemotherapy -- TARGETED THERAPIES -- Epidermal Growth Factor Receptor -- Cetuximab -- Gefitinib -- Erlotinib -- Bevacizumab and Thalidomide -- Anaplastic Lymphoma Kinase -- IMMUNOTHERAPY -- Programmed Death Ligand 1 -- Combining Immunotherapy and Radiotherapy -- RADIOTHERAPY -- Dose -- VOLUMES -- Gross Tumor Volume -- Clinical Target Volume -- Planned Target Volume -- MODALITIES -- Photons: 2-D, 3-D, and Intensity-Modulated Radiotherapy Planning -- Protons -- Carbon Ions -- REFERENCES -- 5 - First-Line Therapy for Wild-Type Patients -- CHEMOTHERAPY -- DURATION OF CHEMOTHERAPY -- BEVACIZUMAB -- MAINTENANCE THERAPY -- IMMUNOTHERAPY -- ELDERLY PATIENTS -- IMPAIRED PERFORMANCE STATUS -- CONCLUSIONS -- REFERENCES -- 6 - Lung Adenocarcinoma: Second-Line Treatment -- INTRODUCTION -- CYTOTOXIC CHEMOTHERAPY-MONOTHERAPY -- Docetaxel -- Pemetrexed -- Other Cytotoxic Agents -- COMBINATION CHEMOTHERAPY -- TARGETED AGENTS -- Epidermal Growth Factor Receptor -- Vascular Endothelial Growth Factor -- Mitogen-Activated Protein Kinase Kinase -- IMMUNOTHERAPY -- Nivolumab -- Pembrolizumab -- Atezolizumab -- CONCLUSION -- REFERENCES -- 7 - Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer -- EPIDEMIOLOGY -- DIAGNOSIS -- TREATMENT -- First- and Second- Generation EGFR TKIs -- ACQUIRED RESISTANCE TO FIRST- AND SECOND-GENERATION TKIS AND THE DEVELOPMENT OF THIRD-GENERATION EGFR TKIS -- CYTOTOXIC CHEMOTHERAPY -- IMMUNE THERAPY -- ADJUVANT THERAPY -- TREATMENT BEYOND PROGRESSION AND OLIGOPROGRESSIVE DISEASE -- CNS METASTASES -- SMALL-CELL LUNG CANCER TRANSFORMATION -- EXON 20 INSERTION MUTATIONS.

TREATMENT OF SELECTED TKI TOXICITIES -- SUMMARY OF CURRENT TREATMENT RECOMMENDATIONS -- FUTURE DIRECTIONS -- REFERENCES -- 8 - Approach to Anaplastic Lymphoma Kinase (ALK) Gene Rearranged Non-Small Cell Lung Cancer (NSCLC) -- INTRODUCTION -- CLINICAL FEATURES OF ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER -- TESTING FOR ANAPLASTIC LYMPHOMA KINASE -- APPROACH TO ADVANCED-STAGE ANAPLASTIC LYMPHOMA KINASE PATIENT -- CRIZOTINIB -- NEXT-GENERATION ALK INHIBITORS IN CRIZOTINIB-TREATED PATIENTS -- NEXT-GENERATION ALK TKIS AS FRONT-LINE THERAPY -- ALECTINIB -- AF-001JP -- JALEX (TABLE 8.3) -- ALEX (TABLE 8.3) -- SUMMARY OF ALEX AND JALEX -- CERITINIB -- OTHER DRUGS -- RESISTANCE TO NEXT-GENERATION ALK INHIBITORS -- SEQUENCE OF ALK INHIBITORS (FIGS. 8.1 AND 8.2) -- NON-ALK-DIRECTED THERAPY -- CENTRAL NERVOUS SYSTEM METASTASES -- MANAGEMENT OF PATIENTS WITH OLIGOMETASTATIC DISEASE -- EARLY-STAGE AND LOCALLY ADVANCED ALK POSITIVE NSCLC -- FUTURE DIRECTIONS -- REFERENCES -- 9 - Targeted Therapy in Non-Small-Cell Lung Cancer (Beyond Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase) -- INTRODUCTION -- ROS1 -- BRAF -- MESENCHYMAL-EPITHELIAL TRANSITION -- RET -- HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 -- NEUROTROPHIN TYROSINE RECEPTOR KINASE-MUTATED NSCLC -- CONCLUSIONS -- REFERENCES -- 10 - Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors -- INTRODUCTION -- PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER -- TREATMENT-NAÏVE ADVANCED NON-SMALL CELL LUNG CANCER -- Early Phase Studies in Treatment-Naïve NSCLC -- Randomized Phase III Studies in Treatment-Naïve NSCLC -- Combination of Chemotherapy and Checkpoint Inhibition -- UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER -- Combination of Radiation and Immunotherapy -- SAFETY AND MANAGEMENT OF TOXICITY -- BIOMARKERS -- Clinicopathologic Markers.

Smoking status -- EGFR Status -- PD-L1 Expression -- Tumor Mutation Burden -- T-Effector Gene Signature Expression -- TREATMENT DURATION -- ONGOING STUDIES/FUTURE DIRECTIONS -- REFERENCES -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- J -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- V -- W.